Booth and colleagues used cohorts to find MS risk genes that are expressed differently in whole blood between MS patients and healthy controls, and they found that ZMIZ1 and EOMES are the most significant two, and that this result can be repeated in other cohorts (13, 15). This evidence concerns the gene ZMIZ1 and myeloid sarcoma.